Da yttrium- 90 danner et stabilt kompleks med ibritumomab tiuxetan, følger biodistributionen af radiomarkøren antistoffets biodistribution.
As yttrium-90 forms a stable complex with ibritumomab tiuxetan, the biodistribution of the radiolabel follows the biodistribution of the antibody.